The American Society of Clinical Oncology (ASCO) today released a clinical practice guide for the prevention of cervical cancer by human papillomavirus (HPV) vaccination. This is the first guide to primary prevention of cervical cancer tailored to multiple regions of the world with different levels of socio-economic and structural resource environments, providing evidence-based guidance to health care providers around the world. The guide includes four levels of advice based on resource settings: basic, limited, enhanced, and maximum. The level relates to the financial resources of a country or region and its health systems, including personnel, infrastructure and access to services. The guide supplements ASCO's other two cervical cancer guidelines and also stratifies to these four resource levels. Main guidance recommendations: Independent of resource settings in all settings, two doses of human papillomavirus vaccine are recommended for girls between 9 and 14 years of age, with a minimum of 6 months between doses and a maximum of 12 to 15 months. HIV-positive girls should receive three doses. For maximum and enhanced resource settings: If a girl over the age of 15 receives the first dose before the age of 15, they can complete two doses; If they do not receive the first dose before the age of 15, they should receive three doses; In both cases, the vaccine can be vaccinated at the age of 26. For limited and basic resource settings: If there is sufficient resources after vaccination for girls between the ages of 9 and 14, girls receiving a dose may receive additional doses between the ages of 15 and 26. Boy Vaccination: In all cases, if there is at least 50% coverage in the female target population, resources are sufficient, the boy can be vaccinated and the vaccination is effective. Cervical cancer is the fourth most common cancer among women worldwide, and it is disproportionately prevalent in less developed regions. In fact, 85% of cervical cancer diagnoses and 87% of cervical cancer deaths occur in underdeveloped regions, including parts of Africa and Latin America. Dr. Silvia de Sanjosé, co-chair of the panel, said: "Because resource availability varies widely within the country, we need to adjust our strategy to improve HPV vaccination." The Català d'Oncologia Institute's Cancer Epidemiology Research Program: "This guide is unique in providing advice on cervical cancer vaccination and can be adapted to different resource levels, and we expect it to have a major impact on the global health community." HPV infection is almost the cause of all cervical cancer in the world. Although it can also cause genital warts and certain other cancers, cervical cancer is by far the most common serious condition associated with HPV infection. Unlike other existing HPV vaccination guidelines, ASCO's guidelines focus on the use of HPV vaccination, specifically for the prevention of cervical cancer. “Although the HPV vaccine has been in existence for more than a decade, in many places, including high-resource countries such as the United States, vaccine intake is not ideal,†the expert group that developed the guide, and the national cancer of Buenos Aires, Argentina. Dr. Silvina Arrossi, an officer and researcher at the institute, said: "As a cancer doctor, ASCO will continue to support the HPV vaccination program and work to help more women in the world accept this very difficult cancer." Natural Field focus on produce Cosmetic Raw material, powder functions as an Antioxidant and whitening in cosmetic products. They can effectively treat freckles, old age spots, pigmentation, acne, delaying senescence and preventing ultraviolet radiation,absorbed by the skin through the cell membrane, and they are very effective as a cosmetic external applicatio. Skin-Whitening Cosmetic Ingredient,Skin-Whitening Powder,Skin-Whitening Extract,Skin Whitening Xi'an Natural Field Bio-Technique Co., Ltd. , https://www.natural-field.com